Clinical Study on the Safety, Efficacy, and Pharmacokinetics of a Universal CD19-Targeted CAR-T Cell Injection (RD06-04) in the Treatment of Patients With Refractory Inflammatory Myopathy and ANCA-Associated Vasculitis
Latest Information Update: 29 May 2025
At a glance
- Drugs RD06 04 (Primary)
- Indications Myositis; Vasculitis
- Focus Adverse reactions
Most Recent Events
- 29 May 2025 New trial record